How do you keep patients on MeziKd when AEs show up? In this Sound Bite, Dr. @JoshuaRichterMD walks through the safety profile of MeziKd and the practical steps he uses to recognize, grade, and manage adverse events in multiple myeloma. Sound Bites delivers free, unbiased 60–90 second video updates from leading oncologists sent straight to your phone. Watch Dr. Richter’s video + sign up for more oncology education: ow.ly/p7W450ZPj5M Every complete view enters you in our monthly giveaway for incredible prizes. So the more you watch, the better your odds. #Oncology #mmsm #MultipleMyeloma #HemeOnc #MedEd

Proud to partner with Hematology Oncology Associates, PC to advance oncology education and support the healthcare providers shaping better cancer care. Read more: ideologyhealth.com/ideology-… #MedEd #HemeOnc #Oncology

The #NashvilleHeme27 Poster Competition is officially open! 🚨Submit your abstract relevant to hematologic malignancies by November 6, 2026 for the chance to present your poster at this 2-day CE-accredited conference ➡️ow.ly/15C750ZPhjg Join the all-star faculty, led by our incredible chairs, Drs. @drjoannarhodes1, @BerdejaJesus, and @KuykendallMd on Feb 18–20, 2027 in Nashville, TN. Send submissions to: ScientificAffairs@ideologyhealth.com #HemeOnc #HematologyResearch #OncTwitter #MedEd

The full #TexasGI26 agenda is now live ➡️ ow.ly/3fMI50ZMmnL! Join chairs Drs. @YJanjigianMD and Scott Paulson, plus over 40 faculty, for the inaugural 2-day CE-accredited conference as we dive into the latest in upper GI, colorectal, pancreatic, liver/biliary, rare tumors, genetics, and more. View the agenda and register for FREE today! @TXGIconference

Dr. @GhaithAbuZeinah explores why essential thrombocythemia matters and the current unmet needs in patient care—a clear look at why ET still leaves real gaps for patients. Sound Bites delivers free, unbiased 60–90 second video updates from leading oncologists sent straight to your phone. Watch Dr. Abu-Zeinah’s video + sign up for more bite-sized oncology education: ow.ly/ww1950ZMJey Every complete view enters you in our monthly iPad Giveaway, so the more you watch, the better your odds. #Oncology #MPN #HemeOnc #MedEd

Dr. @CParkMD at #WorldGU25 made the case that mHSPC now needs care guided by genetic mutation signatures. His take on KIM-1, ctDNA, and how we counsel patients when tests are positive is the kind of practical teaching #WorldGU26 is built around. Join leading GU experts December 3–5, 2026, in Nashville. Free registration is live: ow.ly/aLA550ZMIRl #GUOncology #MedEd #ThrowbackThursday

We’re excited to announce the winners of the #TexasGI26 Poster Competition! 🏅 Congratulations to Drs. @zaryab_riaz, Nicholas Della Marta, Ratika Dogra, @FilippoGhelard, Madeleine Hopson, Nikolas Naleid, Jessica Shostak, Abdullah Sultany, and Chidiebube Ugwu! 👏👏 Join them at the Poster Session & Welcome Reception, November 5 in Austin, TX. Register today! ow.ly/1oBx50ZNyFl

The full #TexasGI26 agenda is now live ➡️ ow.ly/3fMI50ZMmnL! Join chairs Drs. @YJanjigianMD and Scott Paulson, plus over 40 faculty, for the inaugural 2-day CE-accredited conference as we dive into the latest in upper GI, colorectal, pancreatic, liver/biliary, rare tumors, genetics, and more. View the agenda and register for FREE today!

IDEO Xchange: The Phase III MAVERICK trial presented at WCLC26 investigated whether brain MRI surveillance alone is noninferior to surveillance + PCI in patients with SCLC. Do you expect these results to definitively change the approach to PCI in this setting?

IDEO Xchange: Assuming comparable efficacy, which factor would most influence your 1L HER2-targeted therapy choice in HER2m mNSCLC?

IDEO Xchange: Which of the following best reflects your anticipated use of sunvozertinib in patients with EGFR ex20ins?

IDEO Xchange: The SAFFRON study showed significant PFS and OS benefits in patients with acquired MET drivers after osimertinib. Following 1L progression on osimertinib, what percentage of your patients do you expect to undergo tissue re-biopsy once savolitinib is approved?

IDEO Xchange: Under what circumstances are you most likely to consider reintroducing chemotherapy following progression on first-line osimertinib plus chemotherapy?

IDEO Xchange: The MDT-BRIDGE study suggests that MDT reassessment during neoadjuvant therapy may help patients with stage II-III NSCLC complete curative-intent treatment. How likely are you to incorporate planned MDT reassessment into your practice?

🚨 Round two from Seoul! IDEO Xchange is back LIVE tonight at #WCLC26 — grab your phone and vote right here on X as our experts break down EGFRm mNSCLC (sequencing, Exon20ins), HER2m mNSCLC (1L decisions), ROS1 metastatic & ALK resectable disease, and SCLC (use of PCI). Tune in and cast your vote alongside Drs. @StephenVLiu (Chair) @YYElamin @GlopesMd @chulkimMD @VamsiVelcheti @DrewMoghanaki @christine_lovly @drshieldsmd @JoelNealMD @ElaineShumMD @LudaBazhenovaMD @AnaVManana Don't miss it 🔥 #LungCancer

IDEO Xchange: Which data from WCLC26 are you most looking forward to seeing?

IDEO Xchange: Emerging data with daraxonrasib in mNSCLC have generated interest in targeting RAS-driven NSCLC outside of RAS G12C. What unmet need could a successful pan-RAS inhibitor best address?